

# Frank Aboubakar Nana

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5365627/publications.pdf>

Version: 2024-02-01

25  
papers

554  
citations

840119

11  
h-index

794141

19  
g-index

26  
all docs

26  
docs citations

26  
times ranked

640  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations. , 2022, 10, e004374.		13
2	Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations. European Journal of Cancer, 2022, 167, 142-148.	1.3	32
3	Clinical utility and outcomes impact of crystal digital PCR of sensitizing and resistance EGFR mutations in patients with advanced non-small cell lung cancer. Clinical Lung Cancer, 2022, , .	1.1	0
4	Therapeutic depletion of CCR8 <sup>+</sup> tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy. , 2021, 9, e001749.		91
5	Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy. European Journal of Cancer, 2021, 145, 221-229.	1.3	42
6	Safety of systemic anti-cancer treatment in oncology patients with non-severe COVID-19: a cohort study. BMC Cancer, 2021, 21, 578.	1.1	8
7	Follow-up of functional exercise capacity in patients with COVID-19: It is improved by telerehabilitation. Respiratory Medicine, 2021, 183, 106438.	1.3	36
8	Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy. Annals of Oncology, 2021, 32, 1391-1399.	0.6	32
9	Tumor response to EGFR/BRAF/MEK co-inhibition in a patient with EGFR mutated lung adenocarcinoma developing a BRAFV600 mutation as an acquired resistance mechanism. Lung Cancer, 2021, 159, 42-44.	0.9	10
10	Validation of Neutrophil-to-Lymphocyte Ratio Cut-off Value Associated with High In-Hospital Mortality in COVID-19 Patients. International Journal of General Medicine, 2021, Volume 14, 5111-5117.	0.8	17
11	Targeting BRAF Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small-Cell Lung Cancer. Pharmaceutics, 2021, 13, 1478.	2.0	9
12	Macrophages are metabolically heterogeneous within the tumor microenvironment. Cell Reports, 2021, 37, 110171.	2.9	69
13	Lung immunoglobulin A immunity dysregulation in cystic fibrosis. EBioMedicine, 2020, 60, 102974.	2.7	22
14	Effects of exercise therapy in cancer patients undergoing radiotherapy treatment: a narrative review. SAGE Open Medicine, 2020, 8, 205031212092265.	0.7	29
15	Increased Expression and Activation of FAK in Small-Cell Lung Cancer Compared to Non-Small-Cell Lung Cancer. Cancers, 2019, 11, 1526.	1.7	26
16	Role of Focal Adhesion Kinase in Small-Cell Lung Cancer and Its Potential as a Therapeutic Target. Cancers, 2019, 11, 1683.	1.7	38
17	Increased IgA Expression in Lung Lymphoid Follicles in Severe Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 592-602.	2.5	40
18	Therapeutic Potential of Focal Adhesion Kinase Inhibition in Small Cell Lung Cancer. Molecular Cancer Therapeutics, 2019, 18, 17-27.	1.9	28

#	ARTICLE	IF	CITATIONS
19	P1.01-07 Immune-Related Pneumonitis in NSCLC Patients Treated with Immune Checkpoint Inhibitors (ICI): Impact of Previous Thoracic Radiotherapy. Journal of Thoracic Oncology, 2018, 13, S461-S462.	0.5	5
20	P3.12-11 Association of the Lung Immune Prognostic Index (LIPI) with Outcomes for Immune Checkpoint Inhibitors in Diffuse SCLC Patients. Journal of Thoracic Oncology, 2018, 13, S973-S974.	0.5	1
21	OA09.06 Molecular Alterations and Estimated Indoor Radon in NSCLC Patients from the French National Cancer Institute Registry: Radon France Study. Journal of Thoracic Oncology, 2018, 13, S342.	0.5	5
22	P2.13-24 Prospective Efficacy of Osimertinib in Circulating Tumour DNA (ctDNA) T790M-Mutant NSCLC Patients. Journal of Thoracic Oncology, 2018, 13, S807-S808.	0.5	0
23	P1.01-18 Immunosenescence Correlates with Progression upon PD-(L)-1 Blockade (IO) in Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients. Journal of Thoracic Oncology, 2018, 13, S466-S467.	0.5	1
24	P1.07-028 Dual Role of the Focal Adhesion Kinase in Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, S713.	0.5	0
25	P3.15-004 Distinct Role of FAK Kinase and C-Terminal Domains on Small-Cell Lung Cancer Proliferation. Journal of Thoracic Oncology, 2017, 12, S2339.	0.5	0